Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Verrica Parmaceuticals Inc VRCA

Healthcare Biotechnology
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the... see more

Current News (NDAQ:VRCA)

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire 7 days ago

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

GlobeNewswire 8 days ago

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting 

GlobeNewswire May 5, 2026

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

GlobeNewswire May 5, 2026

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

GlobeNewswire April 9, 2026

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 6, 2026

VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm

Business Wire March 20, 2026

VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCA

Business Wire March 20, 2026

Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCA

Business Wire March 19, 2026
View More News ››

Opinion & Analysis (NDAQ:VRCA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VRCA)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway
coolfooldumbguy - September 19, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Executing

http://beyondspx.com/2024/08/01/verrica-pharmaceuticals-inc-nasdaqvrca-executing-on-commercial-launch-of-ycanth-advancing-pipeline/
MikeTester - August 1, 2024
View more Bullboard ››

Green Bridge Metals Corporation

Green Bridge Metals Corporation

Green Bridge Metals Corporation engages in the acquisition, exploration, and development of mining projects in the United ...
View More »

Podcasts